Skip to main content
. 2014 Mar 27;10(3):e1004271. doi: 10.1371/journal.pgen.1004271

Figure 5. Cases with copy number changes in EGFR, MET, and ERBB2.

Figure 5

(a) Copy number profiles of the primary tumor (PT5) and a plasma sample (P5_1) of patient #5, the time interval between both samples is almost 3 years. Both samples show a focal amplification of the MET gene and, furthermore regions on 7p and 17q, harboring the EGFR and the ERBB2 genes, respectively, are gained. The focal amplification on chromosome 12q13.13-12q13.3 does not include the KRAS gene (for further details see text). (b) Plasma-Seq for patient #6 prior to anti-EGFR therapy with cetuximab (P6_1) showed several copy number changes, including gains of 7p (EGFR) and 17q (ERBB2). The time line indicates the low CEA and CA 19-9 levels during treatment with cetuximab. (FOLFOX: FOL-Folinic acid (leucovorin) + F-Fluorouracil (5-FU) + OX-Oxaliplatin (Eloxatin); FOLFIRI: FOL-Folinic acid (leucovorin) + F-Fluorouracil (5-FU) + IRI-irinotecan).